Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

The objective of this study is to demonstrate the feasibility of flotation-based separation to isolate, activate, and expand primary human T cells.

Abstract

The process of isolating T cells from peripheral blood mononuclear cells (PBMCs) to establish ex vivo cultures is crucial for research, clinical testing, and cell-based therapies. In this study, a simple, novel protocol to isolate, activate, and expand T cells from PBMCs ex vivo is presented. This study utilizes functionalized buoyancy-activated cell sorting (BACS) technology to isolate and activate T cells. Briefly, the protocol involves the positive selection of CD3+ cells from leukopak-derived PBMCs, followed by a 48 h co-stimulation with pre-conjugated anti-CD28-bound streptavidin microbubbles (SAMBs) prior to transduction in 24-well plates. Functionalized microbubbles offer a unique opportunity to buoyantly activate cells, leading to proliferative phenotypes that allow for expansion with minimal exhaustion. This technique offers reduced exhaustion because the co-stimulatory microbubbles remain buoyant and return to the top of the culture medium, thus reducing the amount of time that the expanding cells are in contact with the co-stimulatory factors. The results indicate that the isolated and cultured T cells receive enough stimulation to activate and proliferate but not to an extent that leads to overactivation, which then leads to exhaustion, as demonstrated by the presence of excessive PD-1.

Introduction

More than 500 chimeric antigen receptor (CAR)-T cell therapy clinical trials are currently being conducted across the world, and four CAR-T cell therapy products are available on the market1. However, numerous CAR-T cell research and manufacturing needs still exist that must be addressed to improve the efficacy, scalability, and long-term success of these potentially curative therapies2,3,4,5. Adoptive CAR-T cell clinical research and manufacturing begins with T cell isolation from a peripheral blood sample and the su....

Protocol

1. Isolation of T cells with microbubbles using positive selection

NOTE: This protocol details a small-scale CD3+ positive selection approach using SAMBs.

  1. Incubate 3 x 108 commercially obtained PBMCs in 2.5 mL of separation buffer with biotinylated anti-CD3 (OKT3) antibody at a concentration of 25 ng of antibody per 1 million cells (25 ng/M). Gently mix by pipetting up and down, and incubate at room temperature for 10 min.
  2. Add strept.......

Representative Results

T cells were isolated from purchased PBMCs and plated for activation as described in the protocol. The negative control samples (purchased PBMCs) were not activated. These control samples were included to demonstrate the effect that the microbubble activation process had on the experimental samples as compared to the untouched and unstimulated T cell controls, ensuring that the activation markers observed were the result of the added activation factors and were not inherent to the T cells themselves. As per the experimen.......

Discussion

The described protocol allows for the isolation of T cells from PBMC samples and the activation of suspended T cells in culture media with microbubbles. This method relies on functionalized microbubbles whose inherent buoyancy offers a unique opportunity to introduce co-stimulatory signals to cells and activate them while they are suspended in a culture medium, thereby reducing the exposure of the expanding cells to prolonged stimulation; such overstimulation can result in the increased expression of T cell exhaustion ma.......

Acknowledgements

None.

....

Materials

NameCompanyCatalog NumberComments
2-MercaptoethanolGibco21985-023CAS: 60-24-2
Biologix Multi-Well Culture Plates 24-well platesVWR 76081-560
Biotin anti-human CD28 (28.2) AntibodyBiolegend302904
Biotin anti-human CD3 (OKT3) AntibodyBiolegend317320
DPBS, no calcium, no magnesiumGibco14190-136
GlutaMAX SupplementThermofisher35050061
Human Recombinant IL2 BioVision (vwr)10006-122
Lentiviral Particle rLV.EF1.zsGreen1-9Takara Bio0038VCT
LeukopakBioIVTHUMANLMX100-0001129
Normal Human PBMCsBioIVTHUMANHLPB-0002562
Penicillin/Streptomycin 100X for tissue cultureVWR97063-708CAS: 8025-06-7
Polybrene Infection/Transfection ReagentMillipore SigmaTR-1003-GCAS:28728-55-4
Pooled Human AB Serum Plasma Derived Heat InactivatedInnovative ResearchISERABHI100mL
RPMI 1640 Medium, GlutaMAX Supplement, HEPESGibco72400047
Streptavidin Microbubble Kit (includes Akadeum's separation buffer)Akadeum11110-000

References

  1. Albinger, N., Hartmann, J., Ullrich, E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Therapy. 28 (9), 513-527 (2021).
  2. Tyagarajan, S., Spencer, T., Smith, J.

Explore More Articles

T Cell IsolationT Cell ActivationT Cell ExpansionMicrobubblesBuoyancy based SelectionPBMCCD3 AntibodyCD28 AntibodyCell TherapyCell Manufacturing

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved